Sinusoidal obstruction syndrome risk factors: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Sinusoidal obstruction syndrome}} | {{Sinusoidal obstruction syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{HS}} | ||
==Overview== | ==Overview== | ||
Common risk factors in the development of sinusoidal obstruction syndrome are [[stem cell transplantation]], preexisting liver dysfunction and high-dose [[conditioning regimens]]. | Common risk factors in the development of sinusoidal obstruction syndrome are [[stem cell transplantation]], preexisting liver dysfunction and high-dose [[conditioning regimens]]. |
Revision as of 23:34, 8 February 2018
Sinusoidal obstruction syndrome Microchapters |
Differentiating Sinusoidal obstruction syndrome from Other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Sinusoidal obstruction syndrome risk factors On the Web |
American Roentgen Ray Society Images of Sinusoidal obstruction syndrome risk factors |
Directions to Hospitals Treating Sinusoidal obstruction syndrome |
Risk calculators and risk factors for Sinusoidal obstruction syndrome risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
Common risk factors in the development of sinusoidal obstruction syndrome are stem cell transplantation, preexisting liver dysfunction and high-dose conditioning regimens.
Risk Factors
Common risk factors for sinusoidal obstruction syndrome are:[1][2][3]
- Stem cell transplantation
- Preexisting liver dysfunction (elevated transaminases, fibrosis or cirrhosis, low pseudocholinesterase level or low albumin level pretransplantation)
- Presence of hepatic metastases
- Advanced age
- Prior radiation treatment of the liver
- High-dose conditioning regimens
- Allogeneic transplantation (compared with autologous transplantation)
- High dose radiation therapy
- Liver transplantation
References
- ↑ Kumar S, DeLeve LD, Kamath PS, Tefferi A (2003). "Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation". Mayo Clin Proc. 78 (5): 589–98. doi:10.4065/78.5.589. PMID 12744547.
- ↑ McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993). "Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients". Ann. Intern. Med. 118 (4): 255–67. PMID 8420443.
- ↑ Carreras E, Bertz H, Arcese W, Vernant JP, Tomás JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF (1998). "Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party". Blood. 92 (10): 3599–604. PMID 9808553.